🫁💙 Smarter Medications for CHD with Pulmonary Hypertension
Managing congenital heart disease (CHD) alongside pulmonary hypertension (PH) is one of the most complex challenges in cardiovascular care. ❤️🩹 In Japan , clinicians are refining pharmacological strategies to improve survival, reduce complications, and enhance quality of life for patients across all ages. From targeted vasodilators to combination therapies, treatment plans are increasingly personalized, reflecting the growing understanding that every CHD patient has unique hemodynamic needs. 📊💊 Recent insights from the Japanese Association of Congenital Heart Disease Registry (JACPHR) highlight real-world prescribing trends and outcomes. 📘 The registry data reveal how endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs are commonly used either alone or in combination to manage pulmonary pressures effectively. These evidence-based approaches not only stabilize symptoms like breathlessness and fatigue but als...
